Inivata
Inivata's Overview
Inivata Limited is a clinical cancer genomics company that specializes in liquid biopsy. Founded in 2014, Inivata pioneered advancements in the analysis of circulating tumor DNA (ctDNA) to transform cancer patient care through earlier detection, personalized treatment, and monitoring of the disease. Their key technologies include the InVision® liquid biopsy platform and the RaDaR® assay for detecting minimal residual disease (MRD) and recurrence. In June 2021, Inivata was acquired by NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology pharma services. Inivata now operates as a key part of NeoGenomics' liquid biopsy division, strengthening its portfolio in advanced cancer diagnostics and research. The original Inivata website (inivata.com) now redirects to NeoGenomics' liquid biopsy information pages.
Where is Inivata's Headquarters?
HQ Function
Serves as a key research and development site for liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) analysis, now integrated into NeoGenomics' global R&D network. It focuses on developing and validating assays like RaDaR®.
Notable Features:
Located within the prestigious Babraham Research Campus, providing access to state-of-the-art laboratories, a highly collaborative research environment, and a dense cluster of biotech companies and world-class academic institutions.
Work Culture:
As part of NeoGenomics, the Cambridge site likely fosters a culture of cutting-edge innovation, scientific rigor, and interdisciplinary collaboration, driven by the mission to improve cancer patient outcomes. It combines Inivata's agile biotech spirit with NeoGenomics' larger corporate structure focused on precision oncology.
HQ Significance:
The Cambridge site is highly significant for its pioneering work in liquid biopsy, contributing Inivata's proprietary technologies (like RaDaR®) and deep expertise to NeoGenomics' comprehensive oncology diagnostics portfolio. It remains a critical center for ctDNA research, development, and assay validation.
Values Reflected in HQ: The location and facilities reflect values such as scientific excellence, relentless innovation, collaboration with the global oncology community, and a profound commitment to advancing cancer care through leading-edge technology.
Location:
Through its integration with NeoGenomics, Inivata's innovative liquid biopsy technologies, such as the RaDaR® MRD assay, support global clinical trials, provide diagnostic solutions for cancer patients worldwide, and enhance NeoGenomics' pharma services. This includes research and development, CLIA/CAP-accredited clinical testing, and commercialization efforts across North America, Europe, and other international markets via NeoGenomics' extensive operational network and partnerships.
Street Address:
The Jonas Webb Building, Babraham Research Campus
City:
Cambridge
State/Province:
Cambridgeshire
Country:
United Kingdom
Inivata's Global Presence
Research Triangle Park, North Carolina, USA
Address: Historically: 7020 Kit Creek Road, Suite 150, Research Triangle Park, NC 27709, USA. (Operations now integrated into NeoGenomics' RTP facilities)
Served as the North American hub for clinical trial management, regulatory interactions, commercialization efforts for Inivata's liquid biopsy tests, and engagement with the U.S. oncology community and pharmaceutical partners. This expertise and operational capacity now contribute to NeoGenomics' broader U.S. and global strategy.
Buying Intent Signals for Inivata
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Inivata
As of April 2025, Inivata' leadership includes:
Investors of Inivata
Inivata has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Executive changes relevant to Inivata's technologies primarily occur at the NeoGenomics parent company level. In the last 12 months, a key appointment was made to bolster NeoGenomics' scientific leadership. Publicly announced exits specifically impacting the former Inivata operational scope are not prominent.
New Appointments:
Technology (Tech Stack) used by Inivata
Discover the tools Inivata uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Inivata Email Formats and Examples
Historically, Inivata Limited utilized common corporate email formats. While Inivata is now part of NeoGenomics and communications may primarily use @neogenomics.com addresses, understanding historical formats can be useful. A common pattern for Inivata was [first_initial][last].
f[last]@inivata.com
Format
jdoe@inivata.com
Example
70%
Success rate
News and media
NeoGenomics, Inc. • May 23, 2024
NeoGenomics to Showcase Latest Data on Its RaDaR® Assay for Minimal Residual Disease (MRD) Detection at the 2024 ASCO Annual Meeting
NeoGenomics announced it will present new data on its RaDaR® assay, developed from Inivata technology, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations will highlight RaDaR's performance in detecting MRD across various cancer types, demonstrating its potential to personalize patient treatment....more
NeoGenomics, Inc. • October 2, 2023
NeoGenomics Announces Medicare Coverage for its RaDaR® Assay in Muscle-Invasive Bladder Cancer
NeoGenomics announced that Palmetto GBA, a Medicare Administrative Contractor, issued a local coverage determination for the RaDaR® MRD assay (based on Inivata technology) for monitoring muscle-invasive bladder cancer. This decision expands access to the test for eligible Medicare patients....more
NeoGenomics, Inc. • June 15, 2021
NeoGenomics Completes Acquisition of Inivata
NeoGenomics, Inc. announced the successful completion of its acquisition of Inivata Limited. This strategic acquisition was aimed at significantly expanding NeoGenomics' position in the rapidly growing liquid biopsy market, particularly in minimal residual disease (MRD) testing and personalized cancer treatment....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Inivata, are just a search away.